You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 6,562,861


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,562,861
Title: Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Abstract:##STR1## Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<1.mu.M).
Inventor(s): Babu; Yarlagadda S. (Birmingham, AL), Chand; Pooran (Birmingham, AL), Montgomery; John A. (Birmingham, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Application Number:09/555,131
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 6,562,861

Introduction

United States Patent 6,562,861, issued on May 13, 2003, is a patent that has undergone significant scrutiny, particularly in the context of patent term extensions and regulatory review periods. This analysis will delve into the details of the patent's scope, claims, and the broader patent landscape surrounding it.

Patent Overview

The patent in question, U.S. Patent 6,562,861 B1, is associated with a specific product that underwent a lengthy regulatory review process. This process is crucial for understanding the patent's term extension.

Regulatory Review Period and Patent Term Extension

The regulatory review period for the product associated with this patent was extensive. It included a testing phase and a review phase, totaling 3,286 days (approximately 9 years)[1].

  • Testing Phase: This phase lasted 2,924 days.
  • Review Phase: This phase lasted 362 days.
  • Total Regulatory Review Period: 3,286 days.

The patent term extension was calculated based on this regulatory review period. However, there are limitations and adjustments to this extension:

  • Adjustments: Half of the testing phase (1,462 days) was deducted from the total regulatory review period, resulting in a net extension of 1,824 days (approximately 5 years)[1].

Patent Term Extension Calculation

The original expiration date of the patent was December 17, 2018. With the calculated extension, the new expiration date was extended to December 15, 2023, which is within the five-year limit imposed by 35 U.S.C. § 156(g)(6)(A)[1].

Scope of the Patent

The scope of a patent is defined by its claims, which outline the specific invention and its boundaries.

  • Claim Language: The claims of U.S. Patent 6,562,861 B1 are critical in determining the patent's scope. Research suggests that the length and count of independent claims can be metrics for measuring patent scope. Generally, narrower claims are associated with a higher probability of grant and a shorter examination process[3].

Claim Construction and Patentability

Claim construction is a crucial aspect of patent litigation and validity. The claims must be directed to patent-eligible subject matter.

  • Alice Test: The Supreme Court's "Alice" test is used to determine whether claims are directed to abstract ideas, which are not patentable. The test involves two steps: first, determining if the claims are directed to an abstract idea, and second, if so, whether the claims include elements that transform them into a patent-eligible application[2].

Litigation and Disputes

Patents often face litigation challenges, which can impact their scope and validity.

  • Contour IP Holding LLC v. GoPro, Inc.: While not directly related to U.S. Patent 6,562,861, this case illustrates the complexities of patent litigation. It highlights the importance of claim construction and the application of the "Alice" test in determining patent eligibility[2].

Global Patent Landscape

The global patent landscape is evolving, with efforts to harmonize and modernize the patent system.

  • Global Dossier: This service by the USPTO provides access to file histories of related applications from participating IP Offices, facilitating a more integrated global patent system[4].

Public Access and Search Tools

Public access to patent information is essential for understanding the patent landscape.

  • USPTO Public Search Facility: This facility and other resources like the Patent and Trademark Resource Centers (PTRCs) and the Electronic Official Gazette provide comprehensive access to patent and trademark information[4].

Small Claims Patent Court

There have been discussions and studies on the feasibility of a small claims patent court to address the high costs and complexities associated with patent litigation.

  • ACUS Study: The Administrative Conference of the United States (ACUS) conducted a study on the need and structure of a small claims patent court, engaging with various stakeholders and experts in the field[5].

Key Takeaways

  • Regulatory Review Period: The patent term extension for U.S. Patent 6,562,861 B1 was based on a regulatory review period of 3,286 days, adjusted to 1,824 days.
  • Patent Scope: The scope is defined by the claims, with narrower claims generally associated with higher grant probabilities and shorter examination processes.
  • Patentability: Claims must pass the "Alice" test to ensure they are directed to patent-eligible subject matter.
  • Global Harmonization: Efforts like the Global Dossier aim to modernize and integrate the global patent system.
  • Public Access: Resources like the USPTO Public Search Facility and PTRCs provide essential access to patent information.

FAQs

Q: What is the significance of the regulatory review period in patent term extensions?

The regulatory review period is crucial for calculating the patent term extension, as it determines the additional time added to the patent's original expiration date.

Q: How does the "Alice" test impact patent claims?

The "Alice" test determines whether patent claims are directed to abstract ideas, which are not patentable. It ensures that claims include elements that transform them into patent-eligible applications.

Q: What is the Global Dossier, and how does it benefit patent stakeholders?

The Global Dossier is a service that provides access to file histories of related applications from participating IP Offices, facilitating a more integrated and efficient global patent system.

Q: Why is public access to patent information important?

Public access to patent information is essential for stakeholders to understand the patent landscape, conduct thorough searches, and make informed decisions about their intellectual property.

Q: What is the purpose of the ACUS study on a small claims patent court?

The ACUS study aims to explore the feasibility and structure of a small claims patent court to address the high costs and complexities associated with patent litigation, making the process more accessible and efficient for smaller entities.

Sources

  1. Regulations.gov: Application for Extension of U.S. Patent No. 6,562,861 B1 Under 35 U.S.C. § 156.
  2. CAFC: Contour IP Holding LLC v. GoPro, Inc.
  3. SSRN: Patent Claims and Patent Scope.
  4. USPTO: Search for patents.
  5. ACUS: U.S. Patent Small Claims Court.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,562,861

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,562,861

PCT Information
PCT FiledDecember 17, 1998PCT Application Number:PCT/US98/26871
PCT Publication Date:July 08, 1999PCT Publication Number: WO99/33781

International Family Members for US Patent 6,562,861

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016162 ⤷  Subscribe
Austria 425955 ⤷  Subscribe
Australia 2200199 ⤷  Subscribe
Brazil 9813480 ⤷  Subscribe
Canada 2315262 ⤷  Subscribe
China 1282316 ⤷  Subscribe
Cyprus 1109153 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.